Patents by Inventor Aron ROXIN

Aron ROXIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
    Publication number: 20240018110
    Abstract: The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
    Type: Application
    Filed: December 16, 2021
    Publication date: January 18, 2024
    Inventors: François BÉNARD, Kuo-Shyan LIN, Chengcheng ZHANG, David PERRIN, Aron ROXIN, Zhengxing ZHANG, Antoine DOUCHEZ, Pargol DANESHMANDKASHANI, Samson LAI
  • DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF
    Publication number: 20220062446
    Abstract: A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F/18F exchange or a precursor thereof; and optionally a cell-targeting domain.
    Type: Application
    Filed: December 18, 2019
    Publication date: March 3, 2022
    Applicants: Provincial Health Services Authority, The University of British Columbia
    Inventors: David Perrin, Aron Roxin, Mathieu Lepage, Sungjoon Huh, Zhibo Liu, Rajaguru Kandasamy, Francois Benard, Kuo-Shyan Lin, Hsiou-Ting Kuo, Chengcheng Zhang
  • 18/19F-labelled compounds which target the prostate specific membrane antigen
    Patent number: 10882871
    Abstract: This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: January 5, 2021
    Inventors: Francois Benard, Kuo-shyan Lin, David Perrin, Zhibo Liu, Hsiou-ting Kuo, Jinhe Pan, Aron Roxin, Mathieu Lepage
  • 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN
    Publication number: 20190010171
    Abstract: This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
    Type: Application
    Filed: January 10, 2017
    Publication date: January 10, 2019
    Inventors: Francois BENARD, Kuo-shyan LIN, David PERRIN, Zhibo LIU, Hsiou-ting KUO, Jinhe PAN, Aron ROXIN, Mathieu LEPAGE